BeOne Medicines AG (BEIGF)
OTCMKTS
· Delayed Price · Currency is USD
23.75
0.00 (0.00%)
At close: Mar 2, 2026
BeOne Medicines AG Revenue
In the year 2025, BeOne Medicines AG had annual revenue of $5.34B with 40.23% growth. BeOne Medicines AG had revenue of $1.50B in the quarter ending December 31, 2025, with 32.84% growth.
Revenue
5.34B
Revenue Growth
+40.23%
P/S Ratio
6.25
Revenue / Employee
445.25K
Employees
12,000
Market Cap
33.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 559.00K |
| Vaxart | 148.20M |
| BioStem Technologies | 292.21M |
| Nuo Therapeutics | 2.61M |
| Arch Biopartners | 115.29K |
| ZIVO Bioscience | 209.03K |
BeOne Medicines AG News
- 12 days ago - BeiGene (ONC) Q4 Earnings Preview: Revenue Set for Growth - GuruFocus
- 11 months ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
- 1 year ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer - Business Wire